Inhalation CDMO Bespak recently announced that it will close its site in Research Triangle Park, NC, USA by the end of the first quarter of 2025. Bespak spun out from Recipharm earlier this year with the stated purpose of focusing on the transition of MDIs to LGWP propellants.
According to the company’s announcement, it will be moving “selected product development and testing activities” from the North Carolina site to its site in Holmes Chapel, UK, “enabling greater focus on, and responsiveness to, customer needs in its core pressurised Metered Dose Inhaler (pMDI) business.” The company recently promoted the availability of a pilot-scale GMP line for filling MDIs with HFA-152a or HFO-1234ze at the Holmes Chapel facility.
The site in North Carolina site, which included cGMP inhaler manufacturing facilities, was acquired by Recipharm in 2016 when it acquired Kemwell’s CDMO business, which included Cirrus Pharmaceuticals. Kemwell had acquired Cirrus in 2013.
Bespak CEO Chris Hirst commented, “This strategic decision reflects our vision to be the trusted innovation partner and sustainability leader for inhaled and nasal drug delivery and is a natural progression of our evolution as a specialist inhalation CDMO. Operationally, this announcement enables us to fully focus on supporting our customers in their transition to climate-friendly low GWP propellants, creating the agility that is needed in today’s dynamic and competitive global pMDI market.”
Read the Bespak press release.
